These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 30545408)
1. Acquired partial lipoatrophy as graft-versus-host disease and treatment with metreleptin: two case reports. Shibata Y; Nakatsuka A; Eguchi J; Miyamoto S; Masuda Y; Awazawa M; Takaki A; Yoshida R; Yagi T; Wada J J Med Case Rep; 2018 Dec; 12(1):368. PubMed ID: 30545408 [TBL] [Abstract][Full Text] [Related]
2. Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy. Nagayama A; Ashida K; Watanabe M; Moritaka K; Sonezaki A; Kitajima Y; Takahashi H; Yoshinobu S; Iwata S; Yasuda J; Hasuzawa N; Ozono S; Motomura S; Nomura M Front Endocrinol (Lausanne); 2021; 12():690996. PubMed ID: 34135866 [TBL] [Abstract][Full Text] [Related]
3. Case Report: Metreleptin Treatment in a Patient With a Novel Mutation for Familial Partial Lipodystrophy Type 3, Presenting With Uncontrolled Diabetes and Insulin Resistance. Lambadiari V; Kountouri A; Maratou E; Liatis S; Dimitriadis GD; Karpe F Front Endocrinol (Lausanne); 2021; 12():684182. PubMed ID: 34168618 [TBL] [Abstract][Full Text] [Related]
4. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy. Lee JH; Chan JL; Sourlas E; Raptopoulos V; Mantzoros CS J Clin Endocrinol Metab; 2006 Jul; 91(7):2605-11. PubMed ID: 16636130 [TBL] [Abstract][Full Text] [Related]
5. Metreleptin worked in a diabetic woman with a history of hematopoietic stem cell transplantation (HSCT) during infancy: further support for the concept of 'HSCT-associated lipodystrophy'. Adachi M; Muroya K; Hanakawa J; Asakura Y Endocr J; 2021 Apr; 68(4):399-407. PubMed ID: 33229817 [TBL] [Abstract][Full Text] [Related]
6. Temporary resolution of insulin requirement in acquired partial lipodystrophy associated with chronic graft-versus-host disease. Kimura L; Alvarez G; Li N; Pawlikowska-Haddal A; Moore TB; Casillas J; Lee KW Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28371314 [TBL] [Abstract][Full Text] [Related]
7. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin. Diker-Cohen T; Cochran E; Gorden P; Brown RJ J Clin Endocrinol Metab; 2015 May; 100(5):1802-10. PubMed ID: 25734254 [TBL] [Abstract][Full Text] [Related]
8. Partial lipodystrophy: Clinical presentation and treatment. Mosbah H; Vatier C; Vigouroux C Ann Endocrinol (Paris); 2024 Jun; 85(3):197-200. PubMed ID: 38871513 [TBL] [Abstract][Full Text] [Related]
10. Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy. Akinci G; Akinci B Recent Pat Endocr Metab Immune Drug Discov; 2015; 9(2):74-8. PubMed ID: 26556498 [TBL] [Abstract][Full Text] [Related]
11. Diabetes with partial lipodystrophy following sclerodermatous chronic graft vs. host disease. Rooney DP; Ryan MF Diabet Med; 2006 Apr; 23(4):436-40. PubMed ID: 16620274 [TBL] [Abstract][Full Text] [Related]
12. Influence of diet and body weight in treatment-resistant acquired partial lipodystrophy after hematopoietic stem cell transplantation and its potential for metabolic improvement. Ishida E; Horiguchi K; Matsumoto S; Ozawa A; Sekiguchi S; Yamada E Diabetol Int; 2024 Apr; 15(2):290-296. PubMed ID: 38524924 [TBL] [Abstract][Full Text] [Related]
13. A Report of Three Cases With Acquired Generalized Lipodystrophy With Distinct Autoimmune Conditions Treated With Metreleptin. Lebastchi J; Ajluni N; Neidert A; Oral EA J Clin Endocrinol Metab; 2015 Nov; 100(11):3967-70. PubMed ID: 26390101 [TBL] [Abstract][Full Text] [Related]
14. Metreleptin Supplementation for Improving Lipid and Glycemic Profiles in Acquired Diabetes Lipodystrophy: A Case Report. Nagayama A; Ashida K; Moritaka K; Hidaka M; Gobaru M; Tanaka S; Hasuzawa N; Akasu S; Goto Y; Motomura S; Hara K; Tsuruta M; Wada N; Nakayama H; Tajiri Y; Nomura M J Endocr Soc; 2019 Nov; 3(11):2179-2183. PubMed ID: 31720553 [TBL] [Abstract][Full Text] [Related]
15. Clinical features and metabolic derangements in acquired generalized lipodystrophy: case reports and review of the literature. Misra A; Garg A Medicine (Baltimore); 2003 Mar; 82(2):129-46. PubMed ID: 12640189 [TBL] [Abstract][Full Text] [Related]
16. Leptin replacement therapy in the management of lipodystrophy syndromes. Vigouroux C; Mosbah H; Vatier C Ann Endocrinol (Paris); 2024 Jun; 85(3):201-204. PubMed ID: 38871500 [TBL] [Abstract][Full Text] [Related]
17. Acquired partial lipodystrophy with metabolic disease in children following hematopoietic stem cell transplantation: a report of two cases and a review of the literature. Hosokawa M; Shibata H; Hosokawa T; Irie J; Ito H; Hasegawa T J Pediatr Endocrinol Metab; 2019 May; 32(5):537-541. PubMed ID: 31075084 [TBL] [Abstract][Full Text] [Related]
19. Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy. Brown RJ; Valencia A; Startzell M; Cochran E; Walter PJ; Garraffo HM; Cai H; Gharib AM; Ouwerkerk R; Courville AB; Bernstein S; Brychta RJ; Chen KY; Walter M; Auh S; Gorden P J Clin Invest; 2018 Aug; 128(8):3504-3516. PubMed ID: 29723161 [TBL] [Abstract][Full Text] [Related]
20. Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy. Brown RJ; Oral EA; Cochran E; Araújo-Vilar D; Savage DB; Long A; Fine G; Salinardi T; Gorden P Endocrine; 2018 Jun; 60(3):479-489. PubMed ID: 29644599 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]